Anti-Fibrinolytic Drugs - Baltics

Baltics

In the Baltics, the revenue in the Anti-Fibrinolytic Drugs market is forecasted to reach US$14.91m in 2024.
It is expected to demonstrate an annual growth rate (CAGR 2024-2029) of 5.03%, leading to a market volume of US$19.06m by 2029.
When compared globally, United States is anticipated to generate the highest revenue of US$9,858.00m in 2024.
The Baltics are experiencing an increased demand for anti-fibrinolytic drugs due to a rise in surgeries and a growing elderly population.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Fibrinolytic Drugs in the Baltics has been on the rise in recent years.

Customer preferences: Patients in the Baltics are showing a growing preference for Anti-Fibrinolytic Drugs due to their effectiveness in reducing bleeding during surgical procedures. As a result, hospitals and clinics are increasingly prescribing these drugs to patients undergoing surgeries.

Trends in the market: The Anti-Fibrinolytic Drugs market in the Baltics is being driven by the increasing number of surgical procedures being performed in the region. Additionally, the growing awareness about the benefits of these drugs among patients and healthcare professionals is also contributing to the growth of the market.

Local special circumstances: The Baltics region is witnessing a rise in medical tourism, with an increasing number of patients from neighboring countries traveling to the region for medical treatment. This is also contributing to the growth of the Anti-Fibrinolytic Drugs market in the region.

Underlying macroeconomic factors: The Baltics region is experiencing a stable economic growth, which is leading to an increase in healthcare spending. Additionally, the region's aging population is also contributing to the growth of the Anti-Fibrinolytic Drugs market as older individuals are more likely to require surgical procedures that require these drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.